

# 4DMedical to present at NWR Virtual Healthcare Day

24 November 2021

4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”), a medical technology company focused on commercialising its FDA-cleared and TGA-approved respiratory imaging platform, is pleased to announce that Managing Director and CEO Dr Andreas Fouras will be presenting at the NWR Virtual Healthcare Day at 10:50am AEDT today, Wednesday 24 November 2021.

Investors can register for the session at the following link:

[https://us02web.zoom.us/webinar/register/WN\\_OhgvD9\\_oTlaRrJMVBlys7g](https://us02web.zoom.us/webinar/register/WN_OhgvD9_oTlaRrJMVBlys7g)

After registering, you will receive a confirmation email containing information about joining the webinar. A recording will be made available shortly after the conclusion of the webinar at the same link above.

Investors are invited to submit questions prior to the webinar to [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

For more information on the conference click here: <https://nwrconference.webflow.io/>

–ENDS–

Authorised by Andreas Fouras, CEO.

## Contacts

### Corporate

Charlene Stahr  
Company Secretary  
[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

### Investor

Simon Hinsley  
+ 61 401 809 653  
[shinsley@4dmedical.com](mailto:shinsley@4dmedical.com)

### Media

Matthew Wright  
+ 61 451 896 420  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

## About 4DMedical

Based in Melbourne, Australia and Los Angeles, U.S., 4DMedical Limited was founded in 2012 and is listed on the Australian Securities Exchange (ASX:4DX).

4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer. The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnostics is a US\$31 billion per annum global industry. Through its technology, 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.